Skip to main content
. 2017 Jul 12;8(38):63935–63948. doi: 10.18632/oncotarget.19212

Figure 7. Low level of miR-133b and high level of HOXA9 predicted poor prognosis in colorectal cancer patients.

Figure 7

(A) overall survival (OS) rates of miR-133b in 66 patients by Kaplan–Meier analysis with log-rank test (**P < 0.001). (B) overall survival (OS) rates of HOXA9 in 66 patients by Kaplan–Meier analysis with log-rank test (*P = 0.041). (C) Overall survival (OS) rates of three groups based on the expression of miR-133b and HOXA9: miR-133b+/HOXA9- (14 specimens); miR-133b+/HOXA9+, or miR-133b-/HOXA9- (19 specimens); miR-133b-/HOXA9+ (33 specimens).